Report

Divergent Regulation of Dihydrofolate Reductase Between Malaria Parasite and Human Host

Science  19 Apr 2002:
Vol. 296, Issue 5567, pp. 545-547
DOI: 10.1126/science.1068274

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


This article has a correction. Please see:

Abstract

For half a century, successful antifolate therapy against Plasmodium falciparum malaria has been attributed to host-parasite differences in drug binding to dihydrofolate reductase–thymidylate synthase (DHFR-TS). Selectivity may also arise through previously unappreciated differences in regulation of this drug target. The DHFR-TS of Plasmodium binds its cognate messenger RNA (mRNA) and inhibits its own translation. However, unlike translational regulation of DHFR or TS in humans, DHFR-TS mRNA binding is not coupled to enzyme active sites. Thus, antifolate treatment does not relieve translational inhibition and parasites cannot replenish dead enzyme.

  • * To whom correspondence should be addressed. E-mail: rathod{at}chem.washington.edu

View Full Text

Related Content